How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera

Current Hematologic Malignancy Reports

Volumn 11, Issue 5, 2016, Pages 356-367

  Reiter, Andreas ^a   Harrison, Claire ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Hydroxyurea; Interferon; Polycythemia vera; Ruxolitinib

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 2; PEGINTERFERON ALPHA; PIPOBROMAN; RUXOLITINIB; STAT PROTEIN; ANTINEOPLASTIC AGENT; JAK2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; CLINICAL TRIAL (TOPIC); ERYTHROCYTOSIS; GENE MUTATION; HUMAN; MYELOPROLIFERATIVE NEOPLASM; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHLEBOTOMY; POLYCYTHEMIA VERA; PROGNOSIS; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SURVIVAL; THROMBOCYTE COUNT; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; MORTALITY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; ASPIRIN; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; JANUS KINASE 2; POLYCYTHEMIA VERA; PROTEIN KINASE INHIBITORS; PYRAZOLES; SURVIVAL RATE;

EID: 84958777369     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-016-0311-8     Document Type: Review

References (81)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.
2. Stuart BJ, Viera AJ. Polycythemia vera. Am Fam Physician. 2004;69:2139–44.
3. Hensley B, Geyer H, Mesa R. Polycythemia vera: current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013;14:609–17.
4. Passamonti F. How I, treat polycythemia vera. Blood. 2012;120:275–84.
5. Vannucchi AM. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med. 2010;5:177–84.
6. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673–83.
7. Tefferi A. Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? Leukemia. 2011;25:1059–63.
8. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.
9. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.
10. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.
11. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.
12. Kralovics R, Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood. 2005;106:3374–6.
13. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280:22788–92.
14. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.
15. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755–61.
16. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–81. This large multicenter retrospective study showed that life expectancy in patients with PV is significantly shorter than in patients without the disease. It identified predictors of poor survival and presented a prognostic model for patients with PV.
17. Martinelli I, De Stefano V. Rare thromboses of cerebral, splanchnic and upper-extremity veins. A narrative review. Thromb Haemost. 2010;103:1136–44.
18. Vannucchi AM. How I, treat polycythemia vera. Blood. 2014;124:3212–20.
19. Boiocchi L, Mathew S, Gianelli U, et al. Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. Mod Pathol. 2013;26:1577–85.
20. Johansson P, Mesa R, Scherber R, et al. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk Lymphoma. 2012;53:441–4.
21. Scherber R, Dueck AC, Johansson P, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401–8.
22. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109:68–76.
23. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–32.
24. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111:3383–7.
25. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90:162–73.
26. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22:905–14.
27. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–70.
28. Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia. 2008;22:1494–502.
29. Barbui T, Finazzi MC, Finazzi G. Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev. 2012;26:205–11.
30. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33. This article details findings from the CYTO-PV clinical trial, the first randomized study to evaluate the recommended hematocrit target of < 45% in patients with PV. This study demonstrated that aggressively treating to a hematocrit target of < 45% was associated with a significantly lower rate of major thrombosis or death from cardiovascular causes, compared with a hematocrit target of 45% to 50%.
31. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–24.
32. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446–52.
33. Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138:354–8.
34. Caramazza D, Caracciolo C, Barone R, et al. Correlation between leukocytosis and thrombosis in philadelphia-negative chronic myeloproliferative neoplasms. Ann Hematol. 2009;88:967–71.
35. De Stefano V, Za T, Rossi E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol. 2010;85:97–100.
36. Scherber R, Dueck A, Kiladjian JJ, et al. Conventional therapeutic options have limited impact on MPN symptoms: insights from a prospective analysis of the MPN-SAF TSS. Haematologica. 2012;97(suppl 1)[abstract 366].
37. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–103.
38. Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol. 2013;88:665–9.
39. Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J. 2003;4:198–207.
40. Alvarez-Larran A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119:1363–9. This study demonstrated that patients meeting the ELN criteria for resistance to hydroxyurea have a substantial increase in the risk of death and the risk of hematologic transformation. These findings highlight the need for other therapeutic options for patients who are resistant to hydroxyurea.
41. Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013;160:251–4.
42. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21:270–6.
43. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664–70.
44. Alvarez-Larran A, Bellosillo B, Martinez-Aviles L, et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol. 2009;146:504–9.
45. Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126:560–1.
46. Abelsson J, Andreasson B, Samuelsson J, et al. Patients with polycythemia vera have the worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. Leuk Lymphoma. 2013;54:2226–30.
47. Saini KS, Patnaik MM, Tefferi A. Polycythemia vera-associated pruritus and its management. Eur J Clin Invest. 2010;40:828–34.
48. Tobiasson M, Alyass B, Soderlund S, Birgegard G. High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio. Med Oncol. 2010;27:105–7.
49. Kim J, Wessling-Resnick M. Iron and mechanisms of emotional behavior. J Nutr Biochem. 2014;25:1101–7.
50. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148:961–3.
51. Sever M, Newberry KJ, Verstovsek S. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leuk Lymphoma. 2014;55:2685–90.
52. Zhang ZR, Duan YC. Interferon alpha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. Asian Pac J Cancer Prev. 2014;15:1681–4.
53. Heis N, Rintelen C, Gisslinger B, Knobl P, Lechner K, Gisslinger H. The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera. Eur J Haematol. 1999;62:27–31.
54. Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Interferon alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and Perspectives. Curr Drug Targets. 2011;12:392–419.
55. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer. 2006;107:451–8.
56. Larsen TS, Iversen KF, Hansen E, et al. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013;37:1041–5.
57. Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106:2397–405.
58. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–72.
59. Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood. 2013;122:893–901.
60. The PROUD-PV study. In: Proud-PV website. AOP Orphan Pharmaceuticals AG. 2015. http://www.proud-pv.com/proud-pv-study.html. Accessed 24 Aug 2015.
61. Ahn IE, Natelson E, Rice L. Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide. Clin Lymphoma Myeloma Leuk. 2013;13 suppl 2:S300–4.
62. Birgegard G, Besses C, Griesshammer M, et al. Treatment of essential thrombocythemia in europe: an observational study of 3649 high-risk patients in EXELS. Blood. 2014;124 [abstract 1846].
63. Kuriakose ET, Gjoni S, Wang YL, et al. JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. Haematologica. 2013;98:e135–7.
64. Alvarez-Larran A, Martinez-Aviles L, Hernandez-Boluda JC, et al. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol. 2014;93:2037–43.
65. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29:3907–13.
66. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: a ELN and IWG-MRT consensus project. Blood. 2013;121:4778–81.
67. Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs. 2006;66:111–31.
68. Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet. 1988;2:403.
69. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120:513–20.
70. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35. This article reports the primary findings from the RESPONSE study, the first phase 3 randomized study evaluating the efficacy and safety of a JAK inhibitor (ruxolitinib) vs standard therapy in patients with PV who had an inadequate response to or had unacceptable side effects from hydroxyurea. Ruxolitinib was superior to standard therapy in controlling hematocrit, reducing spleen volume, and improving disease-associated symptoms, findings which formed the basis for the approval of ruxolitinib for the treatment of patients with PV who are resistant to or intolerant of HU.
71. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829–33.
72. Harrison CN, Masszi T, Zachee P, et al. Complete hematologic control with ruxolitinib in patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea. European Hematology Association 20th Congress; 11–14 Jun 2015; Vienna, Austria [abstract E1353].
73. Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxyurea therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Poster presented at: 56th ASH Annual Meeting and Exposition; 6–9 Dec 2014; San Francisco, CA [abstract 3168].
74. Vigushin DM, Coombes RC. Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Drug Targets. 2004;4:205–18.
75. Andersen C, Mortensen N, Vestergaard H, Bjerrum O, Klausen T, Hasselbalch H. A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis (PMF) and post-polycythemia vera myelofibrosis (PPV-MF). Haematologica. 2013;98(suppl 1) [abstract P279].
76. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150:446–55.
77. Finazzi G, Vannucchi AM, Martinelli V, et al. A phase II study of givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol. 2013;161:688–94.
78. Spivak JL, Considine M, Williams DM, et al. Two clinical phenotypes in polycythemia vera. N Engl J Med. 2014;371:808–17.
79. Angona A, Alvarez-Larran A, Bellosillo B, et al. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera. Eur J Haematol. 2014;94:251–7.
80. Kiladjian JJ, Masse A, Cassinat B, et al. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia. 2010;24:1519–23.
81. Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372:601–12.